The Immunology and Molecular Biology of Breast Cancer
Though often overlooked, the breast functions as part of the immune system. Normal breast tissue contains not only glandular epithelial cells, adipocytes and blood vessels, but also lymphocytes. There are cells of immune origin present within the breast at all times which continuously release IgA . Additionally, immunoglobulin and possibly T-cell immunity is passed from mother to infant during the time of lactation .
KeywordsBreast Cancer Cytokine Profile Factor Vascular Endothelial Cell Growth Breast Cancer Therapy Tumoricidal Activity
Unable to display preview. Download preview PDF.
- 1.Going JJ, Anderson TJ, Battersby S, MacIntyre CCA. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988;130:152–63.Google Scholar
- 18.Reid SE, Scanlon EF, Murthy MS. Do blood-borne cancer cells contribute to local recurrence? Clin Exp Metastasis 1994;12:91.Google Scholar
- 26.Relf M, LeJeune S, Scott PAE et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor b-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to antiogenesis. Cancer Res 1997;57:963–9.PubMedGoogle Scholar
- 34.Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Tret Rep 1976;60:1749–60.Google Scholar
- 44.Tuttle TM, Anderson BW, Thompson WE, et al. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Ca Res 1998;4:2015–24.Google Scholar
- 45.Cobleigh MA. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Mer Soc Clin Oncol 1998;17:97a (abstract #376).Google Scholar
- 46.Slamon D. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: A randomized multinational controlled phase III trial. Proc Amer Soc Clin Oncol 1998;17:98a (abstract #377).Google Scholar
- 48.Dougall WC, Greene MI. Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein. Cell Biophys 1994;24–25:209–18.Google Scholar